Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (AMPLITUDE-L)
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Sponsor: Hanmi Pharmaceutical Company Limited
Terminated
Sponsor decision to cancel TRIAL, not related to safety concern
Other terminated trials from Hanmi Pharmaceutical Company Limited
- Type 2 Diabetes Mellitus · Phase PHASE3 · Dec 2020
- Type 2 Diabetes Mellitus · Phase PHASE3 · Dec 2020
- Non Small Cell Lung Cancer · Phase PHASE2 · Dec 2020
- Type 2 Diabetes Mellitus · Phase PHASE3 · Nov 2020
- Type 2 Diabetes Mellitus · Phase PHASE1 · Sep 2020
More terminations from Hanmi Pharmaceutical Company Limited
Other Type 2 Diabetes Mellitus trials with similar outcome
Listed as NCT03713684, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains terminated or withdrawn. Sponsored by Hanmi Pharmaceutical Company Limited, it has been updated 23 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
23 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Apr 2021 — Jan 2022 [monthly]
Terminated PHASE3
▶ Show 18 earlier versions
-
Feb 2021 — Apr 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hanmi Pharmaceutical Company Limited
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Birmingham, United States , Bridgeton, United States , Busan, South Korea , Chandler, United States , Changsha, China , Chengdu, China , Daejeon, South Korea , Dallas, United States and 26 more locations